3:57 PM ET
8-K
Regulatory Approval
Ultragenyx Pharmaceutical Regulatory Approval
The FDA has granted standard full approval for Ultragenyx's FAYUVI (rebisufligene etisparvovec-hopf), the first-ever approved treatment for Sanfilippo syndrome Type A (MPS IIIA). This marks the company's second gene therapy approval and resulted in the receipt of a Priority Review Voucher.